Valtrex™ 500 mg film-coated tablets

  • Name:

    Valtrex™ 500 mg film-coated tablets

  • Company:
    info
  • Active Ingredients:

    Valaciclovir hydrochloride

  • Legal Category:

    Product subject to medical prescription which may not be renewed (A)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 15/07/15

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 16/7/2015
print

Print ViewKeyword Search SmPC

GlaxoSmithKline (Ireland) Ltd

GlaxoSmithKline (Ireland) Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name Amoxil Paediatric Suspension Active Ingredients Amoxicillin trihydrate
Medicine Name Amoxil Vial for Injection 500mg Active Ingredients Amoxicillin sodium
Medicine Name ANORO ELLIPTA 55 micrograms/22 micrograms inhalation powder, pre-dispensed Active Ingredients Umeclidinium bromide, Vilanterol trifenatate
Medicine Name Augmentin 250 mg/125 mg film-coated tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 500mg/125mg Film-coated Tablets Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin 875/125mg Film Coated tablets Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin Duo Mixed Fruit 400 mg/57 mg /5 ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Clavulanic Acid
Medicine Name Augmentin DUO Suspension 400/57mg Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name Augmentin Intravenous 1.2g Active Ingredients Amoxicillin sodium, Potassium clavulanate
Medicine Name Augmentin Paediatric 125mg/31.25mg per 5ml Powder for Oral Suspension Active Ingredients Amoxicillin trihydrate, Potassium clavulanate
Medicine Name AVAMYS 27.5 micrograms/spray nasal spray suspension Active Ingredients Fluticasone furoate
Medicine Name Avodart Soft Capsules 0.5mg Active Ingredients Dutasteride
Medicine Name Babyhaler Active Ingredients No Active Ingredients
Medicine Name Bactroban Nasal Ointment Active Ingredients Mupirocin calcium
Medicine Name Bactroban Ointment Active Ingredients Mupirocin
Medicine Name Becotide Evohaler 100 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 250 Active Ingredients Beclometasone Dipropionate
Medicine Name Becotide Evohaler 50 Active Ingredients Beclometasone Dipropionate
Medicine Name Benlysta 120 mg and 400 mg powder for concentrate for solution for infusion Active Ingredients Belimumab
Medicine Name Betnovate C 0.1% / 3% w/w Cream Active Ingredients Betamethasone Valerate, Clioquinol
Medicine Name Betnovate Cream 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Ointment 0.1% w/w Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Cream Active Ingredients Betamethasone Valerate
Medicine Name Betnovate RD Ointment Active Ingredients Betamethasone Valerate
Medicine Name Betnovate Scalp Application 0.1% w/v Cutaneous Solution Active Ingredients Betamethasone Valerate
1 - 0 of 136 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 16 July 2015 SmPC

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 16 July 2015 SmPC

Reasons for updating

  • Change to section 7 - Marketing authorisation holder
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 7 - change to Ireland MAH address

Updated on 15 July 2015 PIL

Reasons for updating

  • New PIL for new product

Updated on 15 July 2015 PIL

Reasons for updating

  • Change to date of revision
  • Change to MA holder contact details

Updated on 24 March 2015 SmPC

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.8 - Update to the HPRA reporting details

Updated on 23 March 2015 PIL

Reasons for updating

  • Change to date of revision
  • Addition of information on reporting a side effect.

Updated on 10 June 2014 SmPC

Reasons for updating

  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.3 - Contraindications
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text
  • Change to improve clarity and readability

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

Section 4.1 - amended to specify that the treatment and suppression of recurrent ocular HSV infections is for immunocompetent adults and adolescents, and immunocompromised adults.
Section 4.3 - Reference to listing in section 6.1
Section 4.8 - Update to reporting adverse reactions

Updated on 9 June 2014 PIL

Reasons for updating

  • Change to instructions about overdose
  • Change to storage instructions
  • Change to side-effects
  • Change to date of revision
  • Change to improve clarity and readability
  • Addition of information on reporting a side effect.

Updated on 12 April 2012 SmPC

Reasons for updating

  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 6.1 - List of excipients

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

5.       PHARMACOLOGICAL PROPERTIES

 

5.1     Pharmacodynamic properties

 

Antivirals for systemic use.

 

Pharmacotherapeutic group: Nucleosides and nucleotides excluding reverse transcriptase inhibitors, ATC code: J05AB11.

 

6.       PHARMACEUTICAL PARTICULARS

 

6.1         List of excipients

 

Tablet core

Microcrystalline cellulose

Crospovidone

Povidone

Magnesium stearate

Silica colloidal anhydrousColloidal silicon dioxide

 

Film coat

Hypromellose

Titanium dioxide

Polyethylene glycolMacrogol 400Macrogol

Polysorbate 80 (500 and 1000 mg tablets only)

Carnauba wax

 

 

 

9.       DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

 

[To be completed nationally]2011-12-15

 

10.     DATE OF REVISION OF THE TEXT

 

2012-01-202011-07-12

Updated on 10 April 2012 PIL

Reasons for updating

  • Change of inactive ingredient

Updated on 4 October 2011 PIL

Reasons for updating

  • Change to side-effects

Updated on 23 September 2011 SmPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

4.8       Undesirable Effects

 

The most common adverse reactions (ARs) reported in at least one indication by patients treated with Valtrex in clinical trials were headache and nausea. More serious ARs such as thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome, acute renal failure and neurological disorders are discussed in greater detail in other sections of the label.

 

Undesirable effects are listed below by body system organ class and by frequency.

 

The following frequency categories are used for classification of adverse effects:

Very common                  ³ 1/10,
Common                         
³ 1/100 and < 1/10,
Uncommon                     
³ 1/1,000 and < 1/100,
Rare                                
³ 1/10,000 and < 1/1,000,
Very rare                         
< 1/10,000.

 

Clinical trial data have been used to assign frequency categories to ARs if, in the trials, there was evidence of an association with valaciclovir.

 

For ARs identified from postmarketing experience, but not observed in clinical trials, the most conservative value of point estimate (‘rule of three’) has been used to assign the AR frequency category. For ARs identified as associated with valaciclovir from post-marketing experience, and observed in clinical trials, study incidence has been used to assign the AR frequency category. The clinical trial safety database is based on 5855 subjects to valaciclovir in clinical trials covering multiple indications (treatment of herpes zoster, treatment/suppression of genital herpes & treatment of cold sores).

 

Clinical Trial Data

 

Nervous system disorders

Very common: Headache.

 

Gastrointestinal disorders

Common:         Nausea.

 

Post Marketing Data

 

Blood and lymphatic system disorders

Uncommon:     Leucopenia, thrombocytopenia.

Leucopenia is mainly reported in immunocompromised patients.

 

Immune system disorders

Rare:    Anaphylaxis.

 

Psychiatric and nervous system disorders

Common:         Dizziness

Uncommon:     confusion, hallucinations, decreased consciousness, tremor, agitation.

Rare:                ataxia, dysarthria, convulsions, encephalopathy, coma, psychotic symptoms, delirium.

 

Neurological disorders, sometimes severe, may be linked to encephalopathy and include confusion, agitation, convulsions, hallucinations, coma. These events are generally reversible and usually seen in patients with renal impairment or with other predisposing factors (see section 4.4). In organ transplant patients receiving high doses (8000 mg daily) of Valtrex for CMV prophylaxis, neurological reactions occurred more frequently compared with lower doses used for other indications.

 

Respiratory, thoracic and mediastinal disorders

Uncommon:     Dyspnoea.

 

Gastrointestinal disorders

Common:         Vomiting, diarrhoea.

Uncommon:     Abdominal discomfort.

 

Hepato-biliary disorders

Uncommon:     Reversible increases in liver function tests (e.g. bilirubin, liver enzymes).

 

Skin and subcutaneous tissue disorders

Common:         Rashes including photosensitivity, pruritus.

Uncommon:     Urticaria

Rare:    angioedema.

 

Renal and urinary disorders

Uncommon:     Renal pain, haematuria (often associated with other renal events).

Rare:                Renal impairment acute renal failure (especially in elderly patients or in patients with renal impairment receiving higher than the recommended doses).

Renal pain may be associated with renal failure.

 

Intratubular precipitation of aciclovir crystals in the kidney has also been reported. Adequate fluid intake should be ensured during treatment (see section 4.4).

 

Additional information on special populations

There have been reports of renal insufficiency, microangiopathic haemolytic anaemia and thrombocytopenia (sometimes in combination) in severely immunocompromised adult patients, particularly those with advanced HIV disease, receiving high doses (8000 mg daily) of valaciclovir for prolonged periods in clinical trials. These findings have been observed in patients not treated with valaciclovir who have the same underlying or concurrent conditions.

Updated on 21 February 2011 PIL

Reasons for updating

  • Change due to harmonisation of patient information leaflet

Updated on 10 December 2010 SmPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 3 - Pharmaceutical form
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.7 - Effects on ability to drive and use machines
  • Change to section 4.8 - Undesirable effects
  • Change to section 4.9 - Overdose
  • Change to section 5.1 - Pharmacodynamic properties
  • Change to section 5.2 - Pharmacokinetic properties
  • Change to section 5.3 - Preclinical safety data
  • Change to section 5.4 - Radiation dosimetry
  • Change to section 6.1 - List of excipients
  • Change to section 6.3 - Shelf life
  • Change to section 6.4 - Special precautions for storage
  • Change to section 6.5 - Nature and contents of container

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

There are changes throughout the SPC but the most significant are:

·         The doses of Valtrex should be reduced in patients with impaired kidney function.

·         The addition of the indication for treatment of herpes zoster and the expansion of the indication to include treatment of ophtalmic zoster, treatment and supression of herpes simplex virus in immunocompetent adults and adolescents and in immunocompromised adults, and treatment and suppression of recurrent ocular HSV infections.

·         The introduction of dose instructions for treatment of herpes zoster and the revision of dose instructions in HSV infections of the skin and mucous membranes in immunocompetent and immunocompromised patients, including the addition of a dose instruction for the treatment of herpes labialis (cold sores).

·         The sections regarding warnings and precautions, interactions, fertility, pregnancy and lactation, side effects, overdose and pharmacological properties have also been revised further to the review of updated clinical data.

 

Updated on 3 December 2010 PIL

Reasons for updating

  • New PIL for new product
  • New PIL for medicines.ie

Updated on 9 April 2010 SmPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 6.2 - Incompatibilities
  • Change to section 8 - MA number
  • Change to section 9 - Date of renewal of authorisation
  • Change to section 10 - Date of revision of the text

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company



Minor editorial updates to the following sections: 4.2 (Table formatting), 6.6 (Full QRD heading used), 8 (Format of PA number updated, number stays the same), 9 (Date of last renewal updated to 02/09/2009) and 10 (Updated to Feb 2010)

Updated on 30 March 2009 SmPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Free text change information supplied by the pharmaceutical company

New text highlighted in Red:

 

 

4.4       Special Warnings and Special Precautions for Use

 

Hydration status: Care should be taken to ensure adequate fluid intake in patients who are at risk of dehydration, particularly the elderly.

 

Use in patients with renal impairment and in elderly patients: Aciclovir is eliminated by renal clearance, therefore the dose of valaciclovir must be reduced in patients with renal impairment (see section 4.2). Elderly patients are likely to have reduced renal function and therefore the need for dose reduction must be considered in this group of patients. Both elderly patients and patients with renal impairment are at increased risk of developing neurological side effects and should be closely monitored for evidence of these effects. In the reported cases, these reactions were generally reversible on discontinuation of treatment (see section 4.8)

 

 Valtrex have not been conducted in liver transplantation; however high dose aciclovir prophylaxis has been shown to reduce CMV infection and disease.

 

Use in genital herpes: Suppressive therapy with valaciclovir reduces the risk of transmitting genital herpes.  It does not cure genital herpes or completely eliminate the risk of transmission.  In addition to therapy with valaciclovir, it is recommended that patients use safer sex practices.

 

4.6       Pregnancy and Lactation

 

Teratogenicity:

Valaciclovir was not teratogenic in rats or rabbits.  Valaciclovir is almost completely metabolised to aciclovir.  Subcutaneous administration of aciclovir in internationally accepted tests did not produce teratogenic effects in rats or rabbits.  In additional studies in rats, foetal abnormalities were observed at subcutaneous doses that produced plasma levels of 100 g/ml and maternal toxicity.

 

Fertility:

Valaciclovir did not affect fertility in male or female rats dosed by the oral route.

 

Pregnancy:

There are limited data on the use of Valtrex in pregnancy. Valtrex should only be used in pregnancy if the potential benefits of treatment outweigh the potential risk.

 

Pregnancy registries have documented the pregnancy outcomes in women exposed to valaciclovir or to any formulation of aciclovir (the active metabolite of valaciclovir); 111 and 1246 outcomes (29 and 756 exposed during the first trimester of pregnancy), respectively, were obtained from women prospectively registered.  The findings of the aciclovir pregnancy registry have not shown an increase in the number of birth defects amongst aciclovir-exposed subjects compared with the general population, and any birth defects showed no uniqueness or consistent pattern to suggest a common cause.  Given the small number of women enrolled into the valaciclovir pregnancy registry, reliable and definitive conclusions could not be reached regarding the safety of valaciclovir in pregnancy.

 

 

4.8       Undesirable Effects

 

Renal and urinary disorders

Rare:                *Renal impairment.

Very rare:        *Acute renal failure, renal pain

Renal pain may be associated with renal failure.

Updated on 28 October 2008 SmPC

Reasons for updating

  • Correction of spelling/typing errors

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 26 August 2008 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 29 March 2007 SmPC

Reasons for updating

  • Improved electronic presentation

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 23 September 2004 SmPC

Reasons for updating

  • Change to section 4.6 - Pregnancy and lactation
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may not be renewed (A)

Updated on 7 July 2003 SmPC

Reasons for updating

  • New SPC for medicines.ie

Legal category: Product subject to medical prescription which may not be renewed (A)